Twist Bioscience represents synthetic DNA platform technology with AI-enabled drug discovery traction and improving gross margins, though profitability timeline uncertainty pressures valuation despite 20% revenue growth.
Financial markets are constantly explained but rarely understood. Every price movement is accompanied by a narrative: inflation fears, growth optimism, geopolitical tension, earnings surprises, technological breakthroughs
November 14, 2025 was a lighter earnings day dominated by Twist Bioscience's synthetic DNA platform story, alongside smaller cap utilities, clinical biotech, lithium producers, and crypto miners—a diverse but lower-profile Friday close-out to the quarterly reporting cycle.
A clear-eyed look at when killing debt brings real relief and when letting money grow elsewhere quietly works harder over time. Read Full Article →
Retirement Systems of Alabama increased its stake in Arthur J. Gallagher & Co. (NYSE:AJG – Free Report) by 13.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 201,076 shares of the financial services provider’s stock
